Improving treatment for chronic myeloid leukemia with targeted therapies
Understanding critical transitions in chronic myeloid leukemia to improve tyrosine kinase inhibitor therapy
This study is looking for ways to help people with chronic myeloid leukemia (CML) respond better to their main treatment, tyrosine kinase inhibitors (TKIs), especially during the first year after they are diagnosed, so that more patients can achieve a lasting remission and possibly a cure.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11016818 on NIH RePORTER |
What this research studies
This research focuses on chronic myeloid leukemia (CML), a type of blood cancer that affects around 5,000 Americans each year. It aims to enhance the effectiveness of tyrosine kinase inhibitors (TKIs), which are the primary treatment for CML, by identifying strategies to improve patient responses during the critical first year after diagnosis. The study will explore the mechanisms behind resistance to TKIs and seek to find ways to help more patients achieve treatment-free remission, potentially leading to a cure. Patients may be involved in understanding their responses to therapy and the factors influencing their treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic myeloid leukemia who are starting treatment with tyrosine kinase inhibitors.
Not a fit: Patients with chronic myeloid leukemia who are not eligible for tyrosine kinase inhibitor therapy or those with advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for CML, enhancing patient outcomes and potentially allowing some patients to stop therapy without relapse.
How similar studies have performed: Previous research has shown promising results in improving treatment outcomes for CML using similar approaches, indicating a potential for significant advancements in this area.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Van Etten, Richard a. — University of California-Irvine
- Study coordinator: Van Etten, Richard a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.